Affibody ‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.

In conclusion, the present study demonstrated the feasibility of using the radiocobalt labeled anti‑EGFR affibody conjugate ZEGFR:2377 as an imaging agent for in vivo visualization of low EGFR‑expressing tumors, like PCa, and for monitoring of receptor occupancy during cetuximab therapy as well as the importance of optimal dosing in order to achieve higher sensitivity molecular imaging. PMID: 30320363 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research